|Alma mater||New College of Florida (B.S., 1987)|
Harvard University (Ph.D., 2001)
|Occupation(s)||Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)|
|Known for||Psychedelic therapy, MAPS|
|Fields||Psychology, Public policy, Political science|
|Thesis||Regulation of the medical use of psychedelics and marijuana (2001)|
|Doctoral advisor||Frederic M. Scherer|
Richard Elliot Doblin (born November 30, 1953) is an American drug activist and executive who is the founder and former executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS).
Life and career
Born in 1953, Doblin grew up in a Conservative Jewish family in suburban Chicago. He is the first of four children to pediatrician Morton Doblin and schoolteacher Arline Doblin. He has three younger siblings, Bruce, Sharon, and Stuart Doblin.
From 1975 until 1982, Doblin owned and operated a company called Braxas Construction, located in the Sarasota, Florida area, which specialized in relocating houses. In 2001 he received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients.
Doblin obtained a psychology degree from New College of Florida in 1987. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner.
He co-founded Earth Metabolic Design Laboratories in 1984 to support psychedelic research and Multidisciplinary Association for Psychedelic Studies (MAPS) in 1986 with the goal of making MDMA an FDA-approved medicine.
Doblin married Lynne Doblin in 1993. Together they have three children Eden, Lilah, and Eliora and live in Boston, Massachusetts.
Rick Doblin's life is profiled in former Washington Post Magazine editor Tom Shroder's book Acid Test: LSD, Ecstasy, and the Power to Heal.
After 37 years, Doblin stepped down as Executive Director of MAPS in February of 2023, replaced by Kris Lotlikar.
As director of MAPS, Doblin has given comment on the publicised serious allegations of sexual assault by MAPS-employed therapists engaging in a clinical trial trialling psychedelic MDMA as therapy for survivors of sexual assault. Four years after Meaghan Buisson submitted a formal complaint to MAPS regarding the series of incidents, Doblin defended the organisation failing to review all videos of the sessions, stating "This unethical sexual misconduct happened after the therapy was over … So that made us think that we didn't need to review the video."
- Frith, C.; Chang, L.; Lattin, D.; Walls, R.; Hamm, J.; Doblin, R. (1987). "Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat". Fundamental and Applied Toxicology. 9 (1): 110–19. doi:10.1016/0272-0590(87)90158-8. PMID 2887476.
- Doblin, R. (1991). "Pahnke's "Good Friday Experiment": A long-term follow-up and methodological critique" (PDF). Journal of Transpersonal Psychology. 23 (1): 1–28. Archived from the original (PDF) on 2014-01-16.
- Doblin, R.; Kleiman, M. (May 1, 1991). "Medical use of marijuana". Annals of Internal Medicine. 114 (9): 809–10. doi:10.7326/0003-4819-114-9-809_3. PMID 1842667.
- Doblin, R.; Kleiman, M. (July 1991). "Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes". Journal of Clinical Oncology. 9 (7): 1314–1319. doi:10.1200/JCO.1922.214.171.1244. PMID 2045870.
- Grinspoon, L.; Bakalar, J.; Doblin, R. (1995). "Marijuana, the AIDS wasting syndrome, and the U.S. government". The New England Journal of Medicine. 333 (10): 670–1. doi:10.1056/nejm199509073331020. PMID 7637743.
- Doblin, R.; Kleiman, M. (1995). "The medical use of marijuana: the case for clinical trials". Journal of Addictive Diseases. 14 (1): 5–14. doi:10.1300/J069v14n01_02. PMID 7543287.
- Doblin, R.; Kleiman, M. (1998). "Survey research vs clinical trials in evaluating the medical utility of marijuana". Southern Medical Journal. 91 (10): 989–91. doi:10.1097/00007611-199810000-00032. PMID 9786301.
- Doblin, R. (1998). "Dr. Leary's Concord Prison Experiment" (PDF). Journal of Psychoactive Drugs. 30 (4): 419–426. doi:10.1080/02791072.1998.10399715. PMID 9924845. S2CID 30462951. Archived from the original (PDF) on 2012-10-30.
- Regulation of the Medical Use of Psychedelics and Marijuana . A dissertation by R. Doblin for his Ph.D. in Public Policy from the Kennedy School of Government, Harvard University. June 2002.
- Doblin, R. (Autumn 2002). "A Clinical Plan for MDMA (Ecstasy) in the Treatment of Post-traumatic Stress Disorder (PTSD): Partnering with the FDA" (PDF). MAPS Bulletin. 12 (3): 5–18.
- Mithoefer, M.; Jerome, L.; Doblin, R. (2003). "MDMA ('ecstasy') and neurotoxicity". Science. 300 (5625): 1504–5. doi:10.1126/science.300.5625.1504. PMID 12791964. S2CID 38721229.
- Summall, H.; Jerome, L.; Doblin, R. (2004). "Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450". Psychopharmacology. 171 (2): 229–30. doi:10.1007/s00213-003-1599-3. PMID 14634709. S2CID 10861824.
- Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Doblin, R. (2010). "The safety and efficacy of 3,4-methylenedioxymethamphetamine assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study" (PDF). Journal of Psychopharmacology. 25 (4): 439–452. doi:10.1177/0269881110378371. PMC 3122379. PMID 20643699.
- Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Martin, S.; Yazar-Klosinski, B.; Michel, Y.; Brewerton, T.; Doblin, R. (2012). "Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study" (PDF). Journal of Psychopharmacology. 27 (1): 28–39. doi:10.1177/0269881112456611. PMC 3573678. PMID 23172889. Archived from the original (PDF) on 2014-06-17.
- Gasser, P.; Holstein, D.; Michel, Y.; Doblin, R.; Yazar-Klosinski, B.; Passie, T.; Brenneisen, R. (2014). "Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases" (PDF). The Journal of Nervous and Mental Disease. 202 (7): 513–20. doi:10.1097/NMD.0000000000000113. PMC 4086777. PMID 24594678. Archived from the original (PDF) on 2014-06-24.
- Psychedelia – Film about the history of psychedelic drugs
- Hausfeld, Russell (2023-04-22). "Rick Doblin Is No Longer MAPS' Executive Director. We Didn't Notice — Did You?". Psymposia. Retrieved 2023-04-24.
- Doblin, Rick (2019-07-09), The future of psychedelic-assisted psychotherapy, retrieved 2022-07-07
- "Meaghan thought psychedelic therapy could help her PTSD. Instead it was the start of a nightmare". ABC News. ABC News (Australia). 25 July 2022. Retrieved 27 July 2022.
- The MAPS Staff
- Erowid character vaults
- Miliard, Mike: This is your brain on drugs: Rick Doblin thinks pot, ecstasy, and other psychedelics could unlock the human mind — and he wants to bring them to Harvard, the FDA, and a doctor's office near you, The Boston Phoenix, Oct. 8–14, 2004.
- Bleyer, Jennifer (October 8, 2013). "Can Ecstasy, Primarily Known as a Club Drug, Help People Suffering From Trauma?". Tablet.
- Cox, Billy (14 August 2008). "Had a nice trip. Wish you could, too". Herald Tribune. Retrieved 2 November 2012.